Last updated: July 28, 2026
CORCEPT THERAPEUTICS v. TEVA (1:23-cv-01505): Litigation Summary, Patent-Issues Map, and Generic Entry Risk
Executive summary:
The docket Corcept Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. (1:23-cv-01505) is a federal Hatch-Waxman patent case filed in 2023. The litigation posture turns on the asserted Orange Book patents tied to Corcept’s Korlym (mifepristone) approvals for Cushing’s syndrome and the defenses typically litigated in this forum: infringement of listed claims, invalidity under 35 U.S.C. §§ 102/103/112, and statutory limits on damages tied to FDA approval timing. The practical outcome sought is a prohibition on Teva’s generic launch until expiration of the asserted patent(s), with Paragraph IV (and any settlement) driving the launch calendar and exclusivity look-through.
What follows is a litigation-focused summary and issue analysis.
What is the case caption and what court controls CORCEPT v. TEVA 1:23-cv-01505?
Case name: Corcept Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc.
Court docket number: 1:23-cv-01505
Year filed: 2023
Parties:
- Plaintiff: Corcept Therapeutics, Inc.
- Defendant: Teva Pharmaceuticals USA, Inc.
Core IP posture (Hatch-Waxman framework):
Cases with this caption typically proceed under 35 U.S.C. § 271(e)(2) after an ANDA challenge to FDA-listed patents for the reference product. The “patent-by-patent” structure matters because each asserted Orange Book patent can carry a different expiration date and different enforceability vulnerabilities. In practice, the case turns on:
- Claim construction
- Infringement of the ANDA product (often limited by structural or method-of-use claim scope)
- Validity challenges (anticipation/obviousness and written description/enablement)
Where the leverage concentrates:
In Korlym-related disputes, leverage often focuses on whether Teva’s proposed ANDA label and proposed manufacturing/formulation fall within the asserted independent claims, and whether secondary patents (formulation or method-of-use) are enforceable versus obviousness or indefiniteness attacks.
What patents are typically asserted in CORCEPT v. TEVA Korlym disputes under the Orange Book?
Featured-snippet answer:
In Korlym (mifepristone) Hatch-Waxman cases, plaintiffs typically assert listed Orange Book patents that map to one or more of the following buckets:
- drug substance or composition claims (formulation/powder/batch-specific composition)
- dosage form claims (tablet-related features such as excipient systems or coating parameters, depending on what is claimed)
- method-of-use claims tied to treating endogenous Cushing’s syndrome
Why this matters for litigation dynamics:
Each patent bucket drives a different infringement and invalidity path:
How formulation patents change the infringement test
If the asserted claims are composition or formulation oriented, Teva’s noninfringement argument is usually that its proposed ANDA formulation deviates in a way that escapes the claim limitations (excipients, particle-size, process parameters, or tablet characteristics). Corcept’s infringement theory usually hinges on ANDA technical sections, product samples, and expert claim-to-process mapping.
How method-of-use patents change the label-and-FDA narrative
If the asserted claims are method-of-use, infringement analysis often flows from the proposed ANDA labeling and clinician treatment guidance contained in the “intended use” section. Teva typically contests whether its label would induce or instruct the claimed treatment.
What is the litigation timeline for 1:23-cv-01505 and how does it affect settlement leverage?
Featured-snippet answer:
The settlement calendar in Paragraph IV cases typically tracks statutory timelines rather than “case milestones” alone. Key timing nodes are:
- filing of the complaint (triggers the automatic stay mechanics if prerequisites are met)
- amended pleadings (often after a claim construction posture forms)
- discovery and expert reports (infringement and validity)
- summary judgment and final trial
Because this prompt does not provide the docket’s event-by-event record, the only actionable timing analysis that can be stated without inventing docket facts is structural: the court’s schedule and the patent-specific expiration dates control leverage more than general case age.
Business impact of timeline:
- If asserted patents are close to expiration, defendants push harder on invalidity and narrow claim constructions.
- If asserted patents have multi-year runway, plaintiffs seek earlier injunctive leverage and higher settlement value to avoid trial risk and to secure exclusivity-like market protection.
How strong is Corcept’s patent estate in Korlym litigation (and what defenses usually win)?
Featured-snippet answer:
Patent strength in Korlym-style disputes is usually assessed by whether the claims survive the three recurrent pressure points:
- prior art novelty/obviousness under §§ 102/103
- written description and enablement under § 112
- definiteness and claim construction coherence
Common defense themes in Hatch-Waxman trials (generic-focused):
- Invalidity via prior art showing the same active regimen, dosing concept, or formulation logic was already taught.
- Design-around latitude where formulation parameters can be modified without sacrificing bioequivalence.
- Indefiniteness and overbreadth attacks on functional language.
Common plaintiff reinforcement themes (brand-focused):
- prosecution history to anchor claim scope
- specific examples in the specification that support enablement
- tight claim construction to avoid prior-art overlaps
Litigation settlement signal that matters commercially:
When defendants concede proximity-to-infringement on a narrowed construction, settlements often price “time-to-launch” rather than a fully defended judgment. That dynamic is typical in Orange Book cases where the parties treat the asserted patents as a risk portfolio.
What generic entry risks exist for Teva if CORCEPT v. TEVA 1:23-cv-01505 is unresolved?
Featured-snippet answer:
The generic entry risk is driven by two gating mechanisms:
- the automatic stay eligibility and duration (where applicable under Hatch-Waxman mechanics)
- whether the asserted patents are ultimately found invalid or not infringed
If the stay expires or is lifted:
Teva’s entry can occur unless restrained by a later injunction or a settlement agreement that preserves launch timing. The commercial exposure is binary: approval and launch often move quickly once the legal gating barrier falls.
If a settlement occurs:
Settlement agreements in Hatch-Waxman typically include one or more of:
- a stipulated entry date
- licensing terms
- covenant not to sue during a defined period
- restrictions on launch strength, labeling, or product geography
Without docket-level settlement terms provided here, no settlement-specific calendar can be stated. The key point is that any settlement converts trial uncertainty into a fixed launch window.
What Paragraph IV and FDA regulatory posture does this case imply for Korlym generics?
Featured-snippet answer:
The case implies Teva filed an ANDA containing a Paragraph IV certification to at least one Orange Book patent for Korlym, triggering this litigation. The litigation then determines whether the FDA approval date and any subsequent launch are blocked.
Why ANDA posture matters in court pleadings:
In Hatch-Waxman, infringement is judged against the proposed ANDA product. That means Teva’s ANDA composition and labeling become central evidence, and Corcept’s asserted claim scope becomes the legal hinge.
How does CORCEPT v. TEVA likely compare with other Korlym patent cases by strategy and issues?
Featured-snippet answer:
Korlym cases typically follow a repeatable strategy stack:
- plaintiff asserts multiple listed patents across formulation/composition and/or method-of-use
- defendant attacks validity across prior art, written description/enablement, and claim construction
- settlement prices a launch window once the claim construction and expert mapping start to converge
Strategic comparison dimensions that affect outcomes:
- how many patents are asserted
- whether at least one asserted patent has a strong infringement pathway
- whether any asserted patent is “easy to design around” (formulation)
- whether the method-of-use claims tie tightly to the proposed ANDA label
What is the Orange Book status of Korlym patents likely at issue here?
Featured-snippet answer:
This case is governed by FDA Orange Book-listed patents for Korlym. The patents’ status dictates the gating effect on generic approval and launch.
What to look for in the Orange Book (mechanically):
- list of patents by number, type (drug substance, drug product, method of use)
- patent expiration dates
- whether any patents are listed for multiple strengths or dosage forms
- whether any are tied to exclusivity periods rather than patent expiry
Because the prompt does not include the Orange Book listing content, no patent numbers or dates can be provided here without risk of inaccuracy.
Key litigation questions courts decide in Hatch-Waxman patent disputes like 1:23-cv-01505
1) Claim construction: what limitations control infringement?
Courts decide whether terms are limited by the intrinsic record. Claim construction can neutralize infringement theories if the asserted claims are interpreted narrowly to a specific formulation/process/therapeutic regimen.
2) Infringement: does Teva’s ANDA fall within the claims?
For product claims, infringement depends on ANDA composition and manufacturing evidence. For method-of-use claims, the proposed label often becomes the operative instrument for infringement.
3) Validity: can Teva knock out all asserted patents?
Defendants aim to invalidate every asserted patent. Plaintiffs aim to keep at least one claim standing to preserve injunctive leverage.
4) Remedies and timing: what can the court actually stop?
Even if infringement is found, the practical remedy is tied to how the FDA approval and launch align with patent expiration and any court orders.
Key Takeaways
- 1:23-cv-01505 is a Corcept v. Teva Hatch-Waxman patent dispute filed in 2023 over Orange Book-listed Korlym patents.
- The litigation’s commercial outcome is determined by (i) which asserted patents remain after claim construction and validity briefing and (ii) whether any automatic stay or settlement converts legal risk into a fixed launch date.
- In Korlym disputes, success typically hinges on whether asserted claims map tightly to Teva’s proposed ANDA product and labeling and whether the asserted patents survive novelty/obviousness and § 112 challenges.
- For generic entry risk modeling, the decision tree is: stay/settlement outcome → patent validity survival → entry timing.
FAQs
1) What does a “Paragraph IV” certification mean for Korlym generics?
It signals the ANDA applicant contends at least one listed Orange Book patent is invalid, unenforceable, or not infringed, triggering a brand-led patent suit.
2) How can claim construction change the result in Korlym patent cases?
A narrow construction can remove key claim limitations from the infringement analysis, shifting the case toward noninfringement or forcing a narrower plaintiff theory.
3) Are method-of-use patents easier or harder to enforce than formulation patents in these cases?
Method-of-use cases depend heavily on the ANDA label and treatment instructions; formulation cases depend heavily on ANDA composition and process evidence. Each typically becomes a different evidentiary fight.
4) What remedies do brands seek in Hatch-Waxman actions like this one?
Brands usually seek orders preventing FDA approval/launch until patent issues resolve, along with injunction-like relief where legal thresholds are met.
5) How do settlements typically affect generic launch timing?
Settlements often set a stipulated entry date, convert litigation uncertainty into a calendar, and include covenants not to sue for a defined period.
References
No sources were provided in the prompt text, and no docket text, court orders, or Orange Book patent lists were included. Therefore, no verifiable citations can be produced without fabricating details.
